Imatinib Bgr

Imatinib, the active ingredient in Imatinib Bgr, is a tyrosine kinase inhibitor presented as an oral tablet for oral administration. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients, targeting malignant cell proliferation and improving survival outcomes.

GNH USA supplies Imatinib Bgr as a licensed, EU‑origin, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product meets European quality standards and is distributed under strict regulatory compliance.

Imatinib is a tyrosine kinase inhibitor used in hematologic and solid‑tumor oncology.

- Chronic myeloid leukemia (CML): Reduces leukemic cell burden and improves long‑term survival. - Gastrointestinal stromal tumor (GIST): Inhibits tumor growth and delays disease progression. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Contributes to molecular remission when combined with chemotherapy. - Myelodysplastic syndrome with PDGFR rearrangement: Induces hematologic response and stabilizes disease.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the hands, feet, or periorbital area. - Muscle cramps or pain: often affecting the lower limbs. - Fatigue: generalized tiredness. - Diarrhea: loose stools occurring intermittently. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Neutropenia or severe leukopenia: increased infection risk. - Hepatotoxicity: elevated liver enzymes or jaundice. - Cardiac failure or reduced left‑ventricular ejection fraction. - Severe hemorrhage: especially in patients with platelet dysfunction. - Pulmonary arterial hypertension: rare but potentially life‑threatening.

Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly.

- Blood counts: Perform complete blood count before treatment and periodically thereafter. - Liver function: Check hepatic enzymes at baseline and during therapy. - Cardiac assessment: Evaluate cardiac function in patients with pre‑existing heart disease. - Hypersensitivity: Discontinue if signs of severe allergic reaction appear. - Renal impairment: Adjust monitoring in patients with reduced kidney function. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Imatinib interacts with several drug classes; awareness helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May raise imatinib plasma levels and increase toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Can lower imatinib concentrations, reducing therapeutic effect. - Warfarin: Concomitant use may enhance anticoagulant effect and raise INR.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam, tacrolimus): May require dose adjustments of the co‑administered drug. - QT‑prolonging agents (e.g., sotalol, quinidine): Monitor ECG for QT interval changes. - Proton‑pump inhibitors: May modestly affect imatinib absorption; assess clinical response.